Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 202-228-8 | CAS number: 93-20-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Acute Oral (OECD 423): LD50 >2000 mg/kg.
Acute Dermal Study (OECD 402): LD50 >2000 mg/kg.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2012
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Compliant with current guidelines and GLP compliant
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Deviations:
- no
- GLP compliance:
- yes
- Test type:
- acute toxic class method
- Limit test:
- yes
- Species:
- rat
- Strain:
- Crj: CD(SD)
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories, Kingston, NY
- Age at study initiation: The female rats were approximately 66 days of age at arrival at the Testing Facility.
- Weight at study initiation: The body weight range was 202 g to 226 g on the day after arrival at the Testing Facility.
- Fasting period before study: Rats were fasted overnight prior to dose administration through 3 to 4 hours postdose administration.
- Housing: The rats were individually housed in stainless steel, wire-bottomed cages.
- Diet (e.g. ad libitum): Ad libitum (except prior to dose administration)
- Water (e.g. ad libitum) Ad libitum:
- Acclimation period: The rats were acclimated for 5 days prior to assignment to study.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): Room temperature was targeted at 66°F to 77°F (19°C to 25°C).
- Humidity (%): The relative humidity was targeted at 30% to 70%.
- Air changes (per hr): The study rooms were maintained under conditions of positive airflow relative to a hallway and independently supplied with a minimum of 10 changes per hour of 100% fresh air that had been passed through 99.97% HEPA filters.
- Photoperiod (hrs dark / hrs light): An automatically controlled 12-hours light: 12-hours dark fluorescent light cycle was maintained.
IN-LIFE DATES: From: To: Dosing was initiated on 29 Aug 2011 and the in-life phase of the study was completed on 26 Sep 2011 - Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: 60 and 400 mg/mL
- Amount of vehicle (if gavage): 5 mL/kg
- Justification for choice of vehicle: This is a common vehicle for this type of substance.
- Lot/batch no. (if required): M-631
- Purity: 100%
DOSAGE PREPARATION (if unusual): A standard procedure was used to prepare the test material.
CLASS METHOD (if applicable) Annex 2c
- Rationale for the selection of the starting dose: It was presumed that test material of this type would not be extremely toxic. - Doses:
- The doses used on study were 300 and 2000 mg/kg.
- No. of animals per sex per dose:
- Six female rats were used at the 300 mg/kg dose level and six female rats were used at the 2000 mg/kg dose level.
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: The female rats were observed and a body weight was recorded on a daily basis.
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight, food consumption and necropsy observations - Statistics:
- Averages and percentages were calculated for this study.
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- All female rats assigned to study survived until scheduled euthanasia.
- Clinical signs:
- other: Clinical observations observed considered test substance-related included: hunched posture was observed in one rat at 300 mg/kg; decreased motor activity, bradypnea, slight excess salivation, ptosis, ataxia and lacrimation were observed at 300 and 2000 m
- Gross pathology:
- No gross lesions were identified at necropsy.
- Interpretation of results:
- not classified
- Remarks:
- Migrated information No mortality was caused at 2000 mg/kg; however, there were adverse clinical signs, body weight loss and decreased food consumption at this dose. Criteria used for interpretation of results: EU
- Conclusions:
- CONCLUSION
In conclusion, administration of a single dose of 300 or 2000 mg/kg of test substance did not cause mortality. Doses of 300 and 2000 mg/kg produced adverse clinical signs that were apparent at the 30 minute postdose observation but were no longer apparent by the end of the day postdose observation. The 2000 mg/kg dose reduced body weight and food consumption the first several days after dose administration. - Executive summary:
Executive Summary
The objectives of this study were to determine the acute toxicity resulting from exposure to EC 202-228-8 (test substance) in Crl:CD(SD) rats, and to estimate the defined exposure ranges where lethality is expected, since death of a proportion of the animals was a major endpoint of this study.
The study design was as follows:
Text Table1
Experimental DesignExposure Group No.
No. of Female Rats
Test Material
Dose Level
(mg/kg)a,b
Concentration
(mg/mL)
Dose Volume
(mL/kg)
1
3
Test Substance
300
60
5
2
3
Test Substance
300
60
5
3
3
Test Substance
2000
400
5
4
3
Test Substance
2000
400
5
a Subsequent dose levels were established by the Study Director based on the results of the initial 300 mg/kg dose.
b Rats were fasted overnight prior to dose administration through 3 to 4 hours after dose administration.
Female rats were administered the test substance once by oral gavage. The rats were fasted overnight prior to dose administration through 3 to 4 hours postdose administration. Doses were adjusted for fasted body weights taken before administration. The first day of dose administration was designated as Day 1 of study (DS 1) for each rat.
The 300 mg/kg dose level was administered to 3 female rats. No mortality and body weight gain were observed; therefore, an additional 3 female rats were dosed once with 300 mg/kg of test substance. No mortality and body weight gain were observed following dose administration; therefore, an additional 3 female rats were dosed once with 2000 mg/kg of test substance. No mortality was observed following dose administration; therefore, an additional 3 female rats were dosed once with 2000 mg/kg of test substance. All doses were based on a 5 mL/kg dose volume.
The following parameters and end points were evaluated in this study: clinical signs, body weights, body weight changes, food consumption, and gross necropsy findings.
Clinical observations observed considered test substance-related included hunched posture, decreased motor activity, bradypnea, slight excess salivation, ptosis, ataxia, lacrimation, impaired righting reflex, low carriage and coldness to the touch. The adverse clinical observations were first observed at approximately 30 minutes postdose. These clinical observations persisted for approximately two hours in the 300 mg/kg dose groups and until the end of day post-checks in the 2000 mg/kg dose groups. All rats appeared normal on DS 2 and continued to be normal for the remainder of the study.
Body weight gains were reduced in the 2000 mg/kg dose groups, as compared with values for the rats in the 300 mg/kg dose groups on DSs 1 to 2. A body weight loss was observed in the 2000 mg/kg dose groups on DSs 2 to 3. A comparable rebound in body weight gain was observed in both 2000 mg/kg dose groups on DSs 4 to 5.
Absolute and relative food consumption values were reduced in the 2000 mg/kg dose groups, as compared with values for the rats in the 300 mg/kg dose groups on DSs 1 to 2, 2 to 3 and 3 to 4. A comparable rebound in absolute food consumption values was observed in both 2000 mg/kg dose groups on DSs 4 to 5 and the absolute and relative food consumption values remained generally comparable for the remainder of the study.
No gross lesions were identified at necropsy.
In conclusion, administration of a single dose of 300 or 2000 mg/kg of test substance did not cause mortality. Doses of 300 and 2000 mg/kg produced adverse clinical signs that were apparent at the 30 minute postdose observation, but were no longer apparent by the end of the day postdose observation. The 2000 mg/kg dose reduced body weight and food consumption the first several days after dose administration.
Reference
Absolute (g/day) and relative (mg/kg/day) food consumption values were reduced in the 2000 mg/kg dose groups, as compared with values for the rats in the 300 mg/kg dose groups on DSs 1 to 2, 2 to 3 and 3 to 4. A comparable rebound in absolute food consumption values was observed in both 2000 mg/kg dose groups on DSs 4 to 5 and the absolute and relative food consumption values remained generally comparable for the remainder of the study including the entire study period (calculated as DSs 1 to 14). The mean absolute food consumption value for the rats in the 2000 mg/kg dose groups (averages of Groups 1 and 2) were reduced by 12% for the first week after dose administration (calculated as DSs 1 to 8), as compared with the mean value for the rats in the 300 mg/kg dose groups (average of Groups 3 and 4).
The mean relative food consumption value for the rats in the 2000 mg/kg dose groups (averages of Groups 1 and 2) were reduced by 19% for the first week after dose administration (calculated as DSs 1 to 8), as compared with the mean value for the rats in the 300 mg/kg dose groups (average of Groups 3 and 4). Absolute and relative food consumption values were generally comparable between the 300 and 2000 mg/kg dose groups during the second week of the study (calculated as DSs 8 to 14).
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
- Quality of whole database:
- Modern GLP study conducted in accordance with OECD test guidelines. Klimisch score 1
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 31 January to 21 February 2012
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Compliant with current guidelines and GLP compliant
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- yes
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River UK, Margate
- Age at study initiation: Approximately 8 to 10 weeks old
- Weight at study initiation: 198 and 230 g (males) and 213 and 232 g (females)
- Fasting period before study: No
- Housing: Singly housed
- Diet (e.g. ad libitum): Ad libitum
- Water (e.g. ad libitum): Ad libitum
- Acclimation period: At least 7 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): Approximately 22°C on each day
- Humidity (%): approximately 32% to 49%.
- Air changes (per hr): 10
- Photoperiod (hrs dark / hrs light): 12 h light/dark cycle
IN-LIFE DATES: From: To: 31 January to 21 February 2012 - Type of coverage:
- occlusive
- Vehicle:
- unchanged (no vehicle)
- Details on dermal exposure:
- TEST SITE
- Area of exposure: ~38 cm2 (males) and ~25 cm2 (females)
- % coverage: ~12% (males), ~8% (females)
- Type of wrap if used: Micropore and Sleek tape
REMOVAL OF TEST SUBSTANCE
- Washing (if done): Sterile water
- Time after start of exposure: 24 h
TEST MATERIAL
- Amount(s) applied (volume or weight with unit): 426 mg (males), 444 mg (females)
- Concentration (if solution): NA
- For solids, paste formed: no - Duration of exposure:
- 24 h
- Doses:
- 2000 mg/kg
- No. of animals per sex per dose:
- 5
- Control animals:
- not required
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: 5 times on the day of dosing and once daily from Day 2 until Day 15
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weights - Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- There were no deaths among animals treated with 2 (2 naphthoxy)ethanol at 2000 mg/kg.
- Clinical signs:
- other: There were no signs of systemic toxicity in any animal at any observation timepoint. Clinical signs were restricted to staining to test site, which was seen in 2 males on Day 2, and test item residues at the test site, which was seen in 4 females on Day 2
- Gross pathology:
- There were no abnormal findings noted at necropsy.
- Interpretation of results:
- not classified
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- Under the conditions of the study, the median lethal dermal dosage (LD50) for 2 (2 naphthoxy)ethanol in Sprague-Dawley rats was estimated to be greater than 2000 mg/kg.
This study is considered to be relevant, reliable and adequate for risk assessment and for classification purposes. - Executive summary:
The objective of this study was to assess the adverse effects which can follow within a short period of time after a single dermal administration of 2-(2-naphthoxy)ethanol to rats.
The test item was administered to a single group of 5 male and 5 female Sprague-Dawley rats. The study design was as follows:
Text Table1
Experimental DesignDose Level
(mg/kg)Animal Numbers
Males
Females
2000
1 to 5
6 to 10
The test item was administered, as supplied, onto the moistened dorsal trunk under a gauze patch, also moistened, which was covered with semi-occlusive tape, then secured with occlusive tape (ie the site was fully occluded). The dressings remained in place for 24 h. The dose was calculated on the basis of the body weights of the animals on the day of dosing. Animals were observed for signs of reaction to treatment 5 times on the day of dosing and once daily from Day 2 until the end of the observation period on Day 15. Body weights were recorded weekly and all animals were subjected to a necropsy examination.
The following parameters and end points were evaluated in this study: clinical signs, body weights, body weight changes, and gross necropsy findings.
There were no unscheduled deaths during the observation period.
There were no systemic signs of toxicity noted in any animal at any observation timepoint and local findings at the dosing site were restricted to staining or test item residues at the test site, which were seen in 6 animals on Day 2 only.
Body weight gain was considered to be acceptable for rats of this age and strain. No abnormal findings were noted at necropsy.
Under the conditions of the study, the median lethal dermal dosage (LD50) for 2-(2-naphthoxy)ethanol in Sprague-Dawley rats was estimated to be greater than 2000 mg/kg.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
Additional information
Acute toxicity oral
Testing conducted in accordance with OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method) reported that no deaths occurred up to an oral dose of EC 202-228-8 at 2000 mg/kg. Doses of 300 and 2000 mg/kg produced adverse clinical signs that were apparent at the 30 minute post dose observation, but were no longer apparent by the end of the day. The 2000 mg/kg dose reduced body weight and food consumption the first several days after dose administration. The median lethal oral dose (LD50) for EC 202-228-8 in Sprague-Dawley rats is therefore greater than 2000 mg/kg.
Acute Dermal Study
Testing conducted in accordance with OECD guideline 402 reported no unscheduled deaths during the observation period. There were no systemic signs of toxicity noted in any animal at any observation timepoint and local findings at the dosing site were restricted to staining or test item residues at the test site, which were seen in 6 animals on Day 2 only. Body weight gain was considered to be acceptable for rats of this age and strain. No abnormal findings were noted at necropsy. Under the conditions of the study, the median lethal dermal dosage (LD50) for EC 202-228-8 in Sprague-Dawley rats was therefore greater than 2000 mg/kg.
Acute Inhalation Study
In accordance with Section 8.5 of Annex VIII of the REACH Regulation, a study of the acute inhalation toxicity is not required, since there is very low potential for inhalation exposure to the substance. Studies of acute toxicity of the registration substance via oral exposure and via dermal exposure have been provided (see sections 7.2.1 and 7.2.3 of the IUCLID dossier).
Justification for selection of acute toxicity – oral endpoint
Modern GLP study conducted in accordance with OECD test guidelines.
Klimisch score 1
Justification for selection of acute toxicity – dermal endpoint
Modern GLP study conducted in accordance with OECD test guidelines.
Klimisch score 1
Justification for classification or non-classification
Acute toxicity oral
Results from a study conducted in accordance with OECD 423 guideline did not produce test-material-related mortality. The acute median lethal oral dose (LD50) was found to exceed 2000 mg/kg, therefore the test material was considered to have no significant acute toxic risk if swallowed and did not meet the criteria for classification according to CLP Regulation (EC) No 1272/2008.
Acute Dermal Toxicity
Results from a study conducted in accordance with OECD 402 guideline did not produce test-material-related mortality.The acute median lethal oral dose (LD50) was found to exceed 2000 mg/kg, therefore the test material was considered to have no significant acute toxic risk if in contact with the skin and did not meet the criteria for classification according to CLP Regulation (EC) No 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.